Royals’ Tejada Suspended 105 Games by MLB for Amphetamine Use

Kansas City Royals infielder Miguel Tejada was suspended for 105 games by Major League Baseball after testing positive for an amphetamine.

The office of MLB Commissioner Bud Selig yesterday announced the suspension, which was to begin immediately.

Tejada, who is currently on the 60-day disabled list with a strained calf, said in a statement released through the Major League Baseball Players Association that he took a banned substance while re-applying to MLB for a Therapeutic Use Exemption.

“I apologize to my teammates, the Royals organization and to the Kansas City fans,” Tejada, 39, said. “I have a medical condition that requires medication to treat. I took that medication while re-applying for a Therapeutic Use Exemption. Under the requirements of the Joint Drug Program, I made a mistake in doing so.”

Yahoo Sports reported Tejada tested positive for Adderall, a stimulant used to treat attention-deficit hyperactivity disorder, or ADHD, and also used by athletes as an energy booster. He had previously tested positive for amphetamines and the 105-game ban is the result of two failed tests again this season, Yahoo Sports said.

USA Today said on its website, citing a person familiar with Tejada’s test results, the six-time All-Star’s exemption expired April 15 and baseball refused to grant him an extension.

Tejada was the American League’s Most Valuable Player while playing for Oakland in 2002. He has a .285 batting average with 307 home runs and 1,302 runs batted in over 16 major-league seasons and signed a one-year contract with the Royals last offseason.

Tejada’s name was mentioned in the 2007 report by former U.S. Senator George Mitchell on the use of performance-enhancing drugs in baseball. Two years later he was fined and was given probation for lying to a congressional investigation into drugs in the sport.

To contact the reporter on this story: Bob Bensch in London at bbensch@bloomberg.net.

To contact the editor responsible for this story: Christopher Elser at celser@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.